XML 37 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - CNY (¥)
¥ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Net revenues ¥ 3,009,845 ¥ 3,473,139 ¥ 3,301,418
Cost of revenues (2,849,487) (3,314,377) (3,161,193)
Gross profit 160,358 158,762 140,225
Other expenses:      
Selling and marketing expenses (68,249) (79,501) (111,454)
General and administrative expenses (75,758) (107,857) (139,385)
Research and development expenses (37,238) (37,947) (57,167)
Total operating expenses (181,245) (225,305) (308,006)
Operating loss (20,887) (66,543) (167,781)
Interest income 3,236 6,037 5,398
Interest expense (2,279) (838) (1,446)
Foreign exchange (losses)/gains 4,805 (2,810) (2,546)
Government grants 1,879 887 12,371
Changes in fair value of warrant 1,476 2,634 1,702
Changes in fair value of amounts due to related party (4,461) (757) (7,524)
Others, net (1,964) (137) (127)
Loss before income tax (18,195) (61,527) (159,953)
Income tax benefit 406 291 363
Net loss (17,789) (61,236) (159,590)
Accretions to preferred shares redemption value (762,169)
Net loss attributable to the Cheche’s ordinary shareholders (17,789) (61,236) (921,759)
Net loss (17,789) (61,236) (159,590)
Other comprehensive income/(loss)      
Foreign currency translation adjustments, net of nil tax (6,892) 4,739 1,621
Fair value changes of amounts due to related party due to own credit risk (354) 197 (405)
Total other comprehensive income/(loss) (7,246) 4,936 1,216
Total comprehensive loss (25,035) (56,300) (158,374)
Accretions to preferred shares redemption value (762,169)
Comprehensive loss attributable to the Cheche’s ordinary shareholders ¥ (25,035) ¥ (56,300) ¥ (920,543)
Net loss attributable to the Cheche’s ordinary shareholders per share      
Basic ¥ (0.22) ¥ (0.78) ¥ (20.30)
Diluted ¥ (0.22) ¥ (0.78) ¥ (20.30)
Basic [1] 82,581,013 78,043,661 45,415,205
Diluted [1] 82,581,013 78,043,661 45,415,205
Share-based compensation expenses included in ¥ (24,352) ¥ (33,869) ¥ (109,983)
Cost of revenues (3) (12) (191)
Selling and marketing expenses (3,053) (5,690) (30,688)
General and administrative expenses (20,443) (26,272) (67,519)
Research and development expenses ¥ (853) ¥ (1,895) ¥ (11,585)
[1] Shares outstanding for all periods reflect the adjustment for Reverse Recapitalization (Note 3).